REMINDER: Our user survey closes on Friday, please submit your responses here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I'm surprised you haven't all been sacked.
i wonder how much of all the “not boosting” ****** was the worm tongue (tp) whispering to him that his company is too expensive and should raise through their grubby little wonga book of “top quality” investors.
Touk, Yes, however, I’m paid per post to prop up sentiment and there is a team of us that rotate aliases. What’s your excuse?
I asked Perplexity 'Does Avacta's affimer technology have applications in cancer therapeutics?'
Answers:
https://www.perplexity.ai/search/Does-Avactas-affimer-QEaVIUCMR66Ko_02dzOKHQ
AS's strategy was in effect to not boost the Sp which was pretty much down to two factors ...1) That Avacta was 'his' company and...2) The disregard he had for the SH base.......I hoping that the new direction that Avacta are taking has amongst other things on its to do list.....some SP boosting
Tomorrow
The flaw in your argument against me and others, is that I have been correct to be cautious and to be able to read more accurately both the market AVCT were trying to sell into during covid and there ambiguous RNS's.
I saw the LFT covid market shrinking way before most here did and therefore realised that the window AVCT for suceesful commercial testing had, was likely to be missed and therefore all the £100 ex china forecasts made here were very likely to be wrong.
Does that make me a fudster or just a bit smarter in my analysis than those that were here at the time?
Regarding this trial, based on the history of AVCT (nothing else just the company's own record), with their continued and so far 100% track record of missing self imposed deadlines, does it make me a fudster to expect that future deadlines are likely to be missed and that if they are, then financing would likely become an issue with the obvious depressing force on the SP?
Does that make me a Fudster being correct or just a bit smarter than the people who keep shouting that I am somehow a plethora of aliases, work for boiler rooms , and generally manipulate the SP?
The theme that I have noticed since being here is that the majority are too thick to understand the most basic rules of investment even when it repeatedly plays out in front of their own eyes year after year.
Limited portfolio and too much capital in any one stock, emotionally involved and seemingly no idea or plan about capital protection.
And as I said up top. my analysis has been broadly correct and that if you are all so conecerned that I might have influenced anyone then all I would have done is save them money.
So what exactly is your point?
That I should have chomped chomped at 160p or bought at 135p as that was never going to be seen again?
That AVCT can't miss? Not to worry how long it takes to monitise this tech assuming it works? To ignore the fact that we know nothing of whats going on behind the scenes?
But as always the height of some posters analysis here, is that it is a few posters on this BB that are soley responsible for the current SP and its fall from 285 over the last 3 years.
Brilliant
Morning so any news as to when this share might go upwards?
Hmmmm
Look more closely at their news flow
https://perspectivetherapeutics.com/newsroom/press-release?i=130069
Strategic agreement and investment in January plus couple of further dilutive raises shortly after totalling 50% is dilution ( I've not done the exact numbers )
It's the way they do it in US they raise and dilute ti increase the overall pie.
The AVCT model upto now has been to try and minimise dilution - there are pros and cons of each method.
Ultimately the moment of truth for either method is when external investment interest from BP is attracted - the jurys out on that at the moment, but maybe not for too much longer.
They have fast track designation on one drug which might explain the sp.
On the basis of this promising preclinical data, VMT-α-NET was awarded Fast Track designation under the FDA’s expedited development program
Boosters! Putting themselves out there, telling people what they're doing and advertising their progress!
I'd love to see Avacta start to do Nasdaq-style detailed quarterly reporting.
We need a NASDAQ listing.
This is an excellent comparison. Perspective Tx started their Phase 1 last year and the first results were out in late 2023 or early 2024. The first cohort had a decent safety profile and the SDMC recommended to move on to the 2nd dose cohort in mid-Jan 2024. Since then, the SP has gained ~300%. The platform was partially proven, hence the investment was significantly de-risked so the SP grew. This is the problem with AIM, such rational responses are simply not seen.
The only real difference that I can see is that Perspective Tx does seem to present at nearly every health/oncology conference under the sun. Whereas, Avacta appear to be very conservative on where/when to present.
Gje306
Yes but never you 🤣
Https://twitter.com/Perspective_Tx/status/1787525768718717298
Fap, a pan cancer target. Indeed, it is.
Incidentally this company is doing rather well with its own tumour targeting product, with a 700% rise since December:
https://www.globenewswire.com/news-release/2023/06/21/2691937/0/en/Perspective-Therapeutics-Initiates-Phase-1-2a-Clinical-Trials-for-Two-Targeted-Alpha-Therapy-Oncology-Product-Candidates.html
Traxpern, every figure has been put forward along the way, from 10p to 10000p. Someone had to be right.
At 1.20 I said this would drop to 50p 9 months ago and nobody listened.
All I got was abuse
The number of posts the dark pom pom wavers must have posted under just their main aliases is insane. All from the bottom of their hearts trying to save us from ourselves. Their obsession just shows how balanced they are, all for the sake of balance of course.. Thorns over 2k posts, post being Ndn l, I mean that’s just cracked.. and we know they’ve got other logins. And Wyn.. seriously I hope the cost of the keyboards you must go through is tax deductible.
Exactly YTeeBack, I'd give up if I were you.
You are absolutely right, and right up there as the three biggest pom pom girls are wyn, thorn and touk, I mean you must really love it to pretty much dedicate your existence to it.
Deutsche Bank has a troubled recent history with regulators and prosecutors. Various sanctions have been imposed on the bank and it has paid big fines re money laundering issues and allegations of enabling tax violations, price fixing and foreign bribery. All according to Google.
I don’t think their advice can be regarded as sound. Best ignored.
Https://twitter.com/Smiffy_O/status/1786395117596651908
Dunno what to make of that.
DB Target price is currently under internal investigation.
Don’t forget the deutsche bank note. This large institution suddenly and completely out of the blue issuing a note on little old Avacta. Definitely smells of intentional price manipulation/suppression. Would make sense if someone is loading up.
Thank Gje, I think it’s obvious to all who that these jobbing fudders are the lowly foot soldiers of people with a bigger plan. I’m not sure they have much bearing here. Most know their game. It is boring as much as anything and clogs up any good research/information